Oct 03, 2019 / 02:05PM GMT
Eliana Rachel Merle - Cantor Fitzgerald & Co., Research Division - Research Analyst
Good morning, everyone. Thank you, very much for joining us today. I'm Ellie Merle, I'm one of the biotech analysts here at Cantor. We are very happy to have Moderna here with us today. Thank you very much for attending.
Lorence H. Kim - Moderna, Inc. - CFO
Thank you for having us.
Eliana Rachel Merle - Cantor Fitzgerald & Co., Research Division - Research Analyst
With us from Moderna is Lorence Kim, the CFO. So thank you very much for joining us.
Questions and Answers:
Eliana Rachel Merle - Cantor Fitzgerald & Co., Research Division - Research AnalystAnd I guess, just to kick it off, you guys have made a lot of progress in the past couple of years and you have a lot of programs in development. Can you sort of frame for us, when you think about your platform kind of some of the technological challenges and the ones that with the positive vaccine data, you feel like you
Trustpilot
